#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Nasopharyngeal cancer Myeloproliferative neoplasm Hepato-lenticular degeneration Leiomyosarcoma metastatic Thyroid cancer metastatic Mitochondrial myopathy Small cell lung cancer limited stage Osteopetrosis Neurofibroma Osteogenesis imperfecta Autoimmune disorder Myxoid liposarcoma Myelofibrosis Deafness Aspergillus infection More trials…

    Learn about Rare Diseases

    Osteosarcoma metastatic Langerhans cell sarcoma – Treatment Friedreich’s ataxia – Basic Information Rosai-Dorfman syndrome Pulmonary sarcoidosis Loeys-Dietz syndrome – Diagnostics Medulloblastoma – Diagnostics Hereditary neuropathic amyloidosis – Basic Information Paroxysmal nocturnal haemoglobinuria – Treatment Kearns-Sayre syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Fenofibrate ANTIMETABOLITES Bosentan Cemiplimab ACETYLCARNITINE HYDROCHLORIDE Mirikizumab PEGZILARGINASE Naltrexone Hydrochloride Clofarabine Lolium Perenne Pollen Extract Nipocalimab MEGESTROL ACETATE Nemolizumab Disulfiram Letetresgene Autoleucel ANXV Cefoxitin Sodium Maralixibat Chloride Amitriptyline Sildenafil More therapies…

    Learn about Your Condition

    Malignant oligodendroglioma Subarachnoid haemorrhage Colorectal cancer stage III Colorectal adenocarcinoma Femoral hernia Mesothelioma malignant COVID-19 Follicular lymphoma stage II Pharyngeal cancer stage II Fallopian tube cancer Dizziness Schizophreniform disorder B-cell type acute leukaemia Spinal muscular atrophy Marfan's syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut De Cancerologie De Lorraine

Institut De Cancerologie De Lorraine

6 Avenue De Bourgogne, Cs 30519, Vandoeuvre Les Nancy, 54519, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Pembrolizumab, Olaparib, and Pemetrexed for Patients with Stage IV Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Olaparib
    Austria France Germany Poland Romania Spain

  • Study on the Safety and Activity of S095029 and Pembrolizumab for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Gastric cancer
    • Oesophageal carcinoma
    Investigated Drugs:
    • Sym025
    • Pembrolizumab
    Austria Belgium Denmark France Hungary Italy +1

  • Study of Trastuzumab Deruxtecan with or without Pertuzumab for Patients with HER2-positive Metastatic Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Docetaxel
    • Paclitaxel
    • Pertuzumab
    Belgium Denmark France Germany Hungary Italy +3

  • Study on Setanaxib and Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Setanaxib
    • Pembrolizumab
    France Italy Poland Spain

  • Study of Durvalumab with Chemotherapy and Radiotherapy for Patients with Unresectable Esophageal Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Oesophageal carcinoma
    Investigated Drugs:
    • Durvalumab
    • Fluorouracil
    • Folinic Acid
    France

  • Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Talazoparib
    • Enzalutamide
    Belgium Bulgaria Czechia Finland France Germany +6

  • Study on Lorlatinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer After First-line Treatment Failure

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IIIB
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Lorlatinib
    France

  • Study on Infertility Risk from Chemotherapy in Young Breast Cancer Patients Using Follitropin Beta and Follitropin Alfa for Egg/Embryo Preservation

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer female
    Investigated Drugs:
    • Follitropin Alfa
    France

  • Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Denmark Finland France Germany +7

  • Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Enfortumab Vedotin
    • Durvalumab
    • Infliximab
    Austria France Germany Greece Italy The Netherlands +3
Previous Page
1 … 14 15 16 17 18
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!